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Abstract
Background: Multilevel spinal fusion surgery has typically been associated with significant blood loss. To limit both
the need for transfusions and co-morbidities associated with blood loss, the use of anti-fibrinolytic agents has been
proposed. While there is some literature comparing the effectiveness of tranexamic acid (TXA) to epsilon
aminocaproic acid (EACA) in cardiac procedures, there is currently no literature directly comparing TXA to EACA in
orthopedic surgery.
Methods/Design: Here we propose a prospective, randomized, double-blinded control study evaluating the effects
of TXA, EACA, and placebo for treatment of adolescent idiopathic scoliosis (AIS), neuromuscular scoliosis (NMS), and
adult deformity (AD) via corrective spinal surgery. Efficacy will be determined by intraoperative and postoperative
blood loss. Other clinical outcomes that will be compared include transfusion rates, preoperative and postoperative
hemodynamic values, and length of hospital stay after the procedure.
Discussion: The primary goal of the study is to determine perioperative blood loss as a measure of the efficacy of
TXA, EACA, and placebo. Based on current literature and the mechanism by which the medications act, we
hypothesize that TXA will be more effective at reducing blood loss than EACA or placebo and result in improved
patient outcomes.
Trial Registration: ClinicalTrials.gov ID: NCT00958581
Background
Multilevel spinal fusion surgery has typically been asso-
ciated with significant blood loss and transfusion
requirements. Significant patient factors affecting opera-
tive blood loss include duration of exposure, severity
and type of spinal deformity, and patient height [1-3].
Surgery dependent factors include operating time, pro-
cedure performed, combined anterior/posterior
approaches, number of vertebrae fused, number of
anchors placed, average mean arterial pressure (MAP)
during surgery, blood salvage techniques, and the use of
anti-fibrinolytic medications [4]. Factors with an unclear
role include, but are not limited to: pre-operative hemo-
globin, autologous donation, history of coagulopathy,
prior use of anticoagulant medication, and type of fibri-
nolytic medication used in the operating room.
Large quantities of intra-operative and postoperative
blood loss require blood transfusion to maintain tissue
perfusion and prevent end-organ damage. The use of
allogenic blood, however, confers an additional risk for
blood borne pathogens. Also noteworthy is the risk for
transfusion related reactions, immune suppression, and
a decrease in coagulation factors. There is also evidence
that transfusion of allogenic blood is increasingly harm-
ful as more blood is transfused [5]. While the innovation
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erythropoietin administration has reduced the need for
allogenic transfusion, patients undergoing spinal fusion
may lose up to their entire blood volume or more for
highly complex spinal reconstructive procedures [6].
More recently the use of anti-fibrinolytics has come
into favor for cardiac and orthopedic surgery where
blood loss is of significant concern. These include apro-
tinin, tranexamic acid (TXA), and epsilon aminocaproic
acid (EACA, trade name Amicar?). Aprotinin is a serine
protease inhibitor with anti-fibrinolytic properties. In
contrast, TXA and EACA are synthetic lysine analogs
that act as inhibitors of fibrinolysis. TXA is ten times
more potent than EACA and binds more strongly to the
plasminogen molecule [7].
The safety of these treatments has been studied in the
orthopedic and cardiac literature [8]. Aprotinin lost
FDA approval due to safety concerns [9]. However, both
TXA and EACA have excellent safety profiles and con-
t i n u et ob eu s e dw i d e l yb ym a n yi n s t i t u t i o n s .I nt h e
spine literature, there continues to be a paucity of data
evaluating the optimal guidelines or indications for
administration of TXA and EACA. No studies offer
level-1 evidence comparing the efficacy of both treat-
ment options head-to-head.
Methods/Design
Trial Organization
This trial will be conducted at single institution, New
York University-Langone Medical Center.
Investigators
All patients are recruited through both the private
offices of the investigators and clinic of New York Uni-
versity - Hospital for Joint Diseases. Patients are con-
sented by the investigators, persons completing research
fellowships in orthopaedic surgery and/or persons work-
ing exclusively on clinical orthopaedic research projects.
These researchers all have experience seeing and con-
senting patients.
Medication Supply and Randomization
On the day of surgery, the anesthesiologist orders
either TXA or EACA from the pharmacy. Orders for
both medications are placed onto a single order form
with both the medical registration number and the
patient’s de-identified identification number (ID). Prior
to study, patient de-identified ID numbers were ran-
d o m l ya s s i g n e dt ot h eT X A ,E A C A ,o rp l a c e b o( 1t o
150) using computer generated random assignment.
Since additional patients with neuromuscular scoliosis
(NMS) and adult deformity (AD) were later included
into the study, supplementary de-identified ID num-
bers were added to the original 150 consecutive de-
identified ID numbers. In a similar fashion, these con-
secutive de-identified ID numbers (151 to 390) were
randomly assigned to TXA, EACA or control. The
updated list of de-identified ID numbers and their
respective treatment groups (TXA, EACA, or Control)
were also placed in a sealed envelope and made avail-
able to the physicians, anesthesiologists, and residents
involved with patient care. A copy was also given to
the pharmacy department and to the researchers in a
sealed envelope. The list of de-identified ID numbers
and their treatment groups will remain unchanged for
the duration of the study. Based upon the identifica-
tion number and the randomization list, the pharma-
cist prepares TXA, EACA, or placebo using the
methods listed in this protocol.
Physician Blinding
While clinicians are blinded to the patient’s particular
treatment group, at any time during surgery or in the
post-operative period any clinician can be “unblinded”
to the patient’s treatment group if there is a concern for
a complication. In addition, all patients are followed
daily by the residents and fellows on the spine service
and will also be followed by spine research fellows car-
ing for the patient. The research residents also record
and document basic metabolic profile (BMP) and com-
plete blood count (CBC) lab values daily. The research
fellows pay careful attention to the blood creatinine and
blood urea nitrogen/creatinine ratio (BUN/Cr) monitor-
ing daily for possible renal failure. Sequential compres-
sion devices (SCD) are given to all spine patients and
they are encouraged to mobilize out of the hospital bed
on post-op day 2. Spine patients are closely monitored
for signs of a DVT by the medicine attending physicians
and nurses caring for patients.
The anesthesiologist, surgeon, and researcher can be
u n b l i n d e df r o mt h es t u d ya ta n yt i m ei nt h ec a s eo fa n
apparent or suspected medical emergency. A copy of
the consent form is placed in every chart in addition
to a list of contact numbers of research persons
involved with the study. There is also a note on the
front cover of the chart informing all nurses and physi-
cians that the patient is enrolled in the study with con-
tact information for the research fellows and for the
pharmacy department. The pharmacy is instructed to
release the treatment group for any patient if requested
by medical personnel caring for the patient or a spine
research fellow. Order forms given to the pharmacy
will be kept in a secure binder and will be made avail-
able upon request. As an additional resource, all physi-
cians, anesthesiologists, and residents involved with
patient care will have access to a sealed envelope with
patient de-identified ID numbers and their assigned
treatment groups.
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Complications include but are not limited to: suspected
medication or allergic reaction, suspected myocardial
infarction, stroke, deep vein thrombosis, pulmonary
embolism, and renal failure. Other side effects that have
been reported have been minor including headache,
upset stomach, flushing, and hypotension. To date there
has been no clear association between the use of anti-
fibrinolytics, such as TXA and EACA, and renal failure
or thrombosis [7,8]. A similar medication with anti-fibri-
nolytic properties, aprotinin, did lose FDA approval over
concerns regarding renal failure in cardiac patients and
the theoretical risk of thrombosis [9]. Aprotinin func-
tions as a serine protease inhibitor. In contrast, TXA
and EACA are synthetic lysine analogs that bind to and
produce a structural change in plasminogen preventing
conversion of plasminogen to plasmin and conversion of
fibrinogen to fibrin. TXA and EACA therefore have a
dual mechanism of anticoagulation: decreased fibrinoly-
sis and decreased platelet aggregation due to the inacti-
vation of plasmin. This difference in mechanism most
likely accounts for the lack of association between the
use of anti-fibrinolytics and renal failure [7,8]. Regard-
less, patients in the study are carefully monitored for
signs of renal failure post-operatively. Any patient with
an elevated or rising creatinine is carefully followed by
resident and attending orthopaedic surgeons, internal
medicine physicians, and the research fellows. If the ele-
vation in creatinine is suspicious for renal failure,
patients will be “unblinded” and treated appropriately.
TXA and EACA have been used most in cardiac and
spinal surgery and meta-analysis has clearly shown a
reduction of intra-operative blood loss and allogenic
transfusion rate with these medications [6-8,10,11,13].
Considering the reported reduction in operative blood
loss and allogenic transfusion rate in both the cardiac
and spine literature, the benefits of treatment outweigh
the potential side effects. While these medications are
widely used, they are currently not the standard of care
in spinal surgery. This study aims to delineate the bene-
fits of TXA versus EACA in spinal surgery, which may
help to identify the patients most in need of this treat-
ment. Complications will be diligently recorded and
reported in the final manuscript.
Ethics, informed consent, and safety
The Institutional Review Board (IRB) of NYU approved
the research protocol. If the patient wishes to enroll in
the study, the IRB approved informed consent process is
undertaken. A copy of the signed informed consent is
issued to the family during the pre-operative office visit.
T h ec o n s e n tf o r mi n c l u d e st h ep u r p o s eo ft h es t u d y ,a
description of the study, costs and reimbursements,
potential risks and discomforts as well as the primary
investigators’ contact information. If the patient is a
minor, consent is obtained from the guardian of the
minors using an NYU IRB approved consent form. Con-
sent is also obtained from minors using an NYU IRB
approved consent form.
Consented individuals are informed of the use of anti-
fibrinolytic medication to control intra-operative and
postoperative bleeding. The risks, benefits, advantages,
and disadvantages of the use of TXA versus EACA ver-
sus placebo to control blood loss are detailed with the
patient and family, as part of their routine pre-operative
visit with their surgeon. The patient and family are dili-
gently informed that while TXA and EACA have indivi-
dually been shown to reduce total blood loss, neither
medication is recognized as the standard of care. The
relative affect of these medications with relation to
transfusion rate and patient outcomes is also not fully
known.
Patient selection
The study concerns patients undergoing thoracic and/or
lumbar spinal surgery for the correction of adolescent,
idiopathic scoliosis (AIS), neuromuscular scoliosis
(NMS), and adult deformity (AD). Inclusion and Exclu-
sion criteria are included in Table 1.
The maximum total number of patients enrolled will
be 150 of AIS (50 in each treatment arm), 90 for NMS
(30 in each treatment arm), 150 for AD (50 in each
treatment arm). These numbers were estimated by criti-
cally reviewing the existing spine and cardiac literature
comparing TXA and EACA against placebo [6-20]. A
power analysis was conducted using the literature to
determine the number of patients necessary to attain
significant results (Tables 2 and 3).
Study Design
The study is designed as a prospective, randomized,
double-blinded control trial. The patient, researcher,
surgeon, and anesthesiologist will all be blinded to the
patient’s treatment. Patients will either receive TXA,
EACA, or normal saline. The study will determine and
compare differences in blood loss intra-operatively and
estimate blood loss postoperatively through monitoring
of subfascial Hemovac drain outputs at the incision site
between the three groups. Postoperatively, laboratory
values, drain outputs, and clinical outcomes will be care-
fully followed.
The primary goal of this study is to compare the effi-
cacy of TXA to EACA to placebo in patients undergoing
corrective spinal surgery for adolescent idiopathic sco-
liosis (AIS), neuromuscular scoliosis (NMS), and with
adult deformity (AD). Outcome measures will include
intra-operative and perioperative blood loss, transfusion
rates, complete blood counts, and coagulation profiles,
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and length of stay.
Standardized treatment protocol
The infusion is started 15 minutes prior to incision. The
infusion is given in two parts. First a loading dose is
given over 15 minutes at a volumetric rate of 20 ml/
hour for a 50 kg patient. Following the initial loading
dose, a maintenance dosage is given at one-tenth of the
loading dose or 2 ml/hour for a 50 kg patient. This
volumetric rate is adjusted accordingly for the patient’s
body weight. The volume infused remains constant
regardless of whether the patient is receiving TXA,
EACA, or saline. TXA is administered at 10 mg/kg hr
for a loading dose followed by 1 mg/kg hr for a mainte-
nance dose. In contrast, EACA is administered at 100
mg/kg hr for a loading dose, followed by 10 mg/kg hr
for a maintenance dose. To adjust for this difference,
the pharmacy is instructed to prepare the EACA at a
tenfold higher concentration (250 mg/ml) than the TXA
(25 mg/ml). The TXA and EACA treatments are both
prepared in saline and both treatment preparations are
visually indiscernible from saline alone. The loading and
maintenance doses for TXA and EACA used in the pro-
tocol are in accordance with recent literature citing effi-
ciency and safety at these dosages [7,8,10-14]. The
literature also reports safely using TXA at a 100 mg/kg
loading dose followed by a 10 mg/kg hr maintenance
dose. However, improved efficacy at this higher dose of
TXA has not been proven in a single orthopedic study.
Since TXA is reported to be ten times more potent than
EACA, delivering a dose of TXA that is ten times smal-
ler than EACA is valid and well supported in the
literature.
Surgical correction of the spine
Dorsal lumbar access is achieved by a posterior lumbar
skin incision along the midline. Paravertebral muscles
are dissected away from bony structures taking care to
achieve adequate hemostasis. Multi-level spinal
Table 1 Inclusion and Exclusion Criteria
All Participants
Inclusion Exclusion
1. Undergoing thoracic and/or lumbar surgery for correction of
condition via posterior spinal fusion of greater than 6 levels
1. No renal dysfunction identified by elevated blood urea nitrogen (BUN)
and creatinine (CR) or BUN to CR ratio greater than 20:1
2. Hold religious and/or other beliefs limiting blood transfusion
3. Currently use anti-coagulant medication or have past medical history
leading to abnormal coagulation profile pre-operatively
4. Significant past medical history preventing the use of TXA or EACA
described in the protocol
AIS
Inclusion Exclusion
1. Between 10 and 21 years of age 1. Previous corrective spinal surgery that is being revised
2. BMI between 5th and 95th percentiles
AD
Inclusion Exclusion
1. Between 18 and 80 years of age 1. Any history of coronary artery disease with stent placement
NMS
Inclusion Exclusion
1. Between 10 and 80 years of age 1. Congenital and syndromic scoliosis
2. Previous corrective spinal surgery that is being revised
Table 2 Power study to determine number of patients needed in AIS group
TXA Amicar Control
Blood
loss
Standard
Deviation
Blood
Loss
Standard
Deviation
Blood
Loss
Standard
Deviation
Sample Size
Needed
Intra-op blood loss 1072 mL +/- 425 mL - - 1420 mL +/- 644 mL 58
Intra-op blood loss 1072 mL +/- 425 mL 893 mL +/- 220 mL - - 80
Total blood
transfused
1253 mL +/- 884 mL - - 1784 mL +/- 733 mL 55
Total units
transferred
- - 1.2 U +/- 1.1 U 2.2 U +/- 1.3 U 34
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structures are performed to increase mobility of the
spinal column. Bone grafts consisting of autologous
bone or allograft are filled in to allow for bony fusion of
the spinal column and limit motion. Pedicle screws are
placed segmentally into vertebral bodies to provide ade-
quate fixation of rod instrumentation. Stainless steel,
titanium, or cobalt rods are placed to help correct and
stabilize the spine while fusion occurs. Generally the
greatest blood loss occurs during dissection and place-
ment of pedicle screws while rod placement is asso-
ciated with less blood loss. Subfascial Hemovac or
Jackson-Pratt drains are placed at the wound site during
closure to allow for adequate drainage and determina-
tion of post-operative blood loss.
Investigation schedule and follow-up
Data will be collected pre-operatively regarding individual
patient demographics, laboratory values, and the surgical
procedure to be performed. Intra-operatively, data will be
gathered to estimate blood loss and account for changes
in fluid balance. Anesthesiologists are asked to maintain a
MAP of 60 during the surgical exposure and anchor place-
ment and a MAP of 70-90 during the surgical correction.
Similarly, surgeons are asked to place only subfascial
Hemovac drains at the incision site. These are both stan-
dard practice and have been shown by our group to help
control blood loss during surgical exposure [21]. Post-
operatively, laboratory values, drain output, and clinical
outcomes are carefully followed until the patient is dis-
charged. Given the increased risk of renal failure with the
use of Aprotinin [7] changes in BUN to CR ratio are care-
fully monitored post-operatively. This data is recorded
onto a de-identified data collection sheet by the research-
ers. These patient data sheets are then entered onto a pro-
tected electronic database, while the data sheets are stored
as a back-up until the study is complete. Once the com-
pleted database is analyzed and summarized, the results
will be presented to the involved participants without any
identifiable patient information.
Statistical considerations
While useful, this analysis is limited by the great varia-
bility in study design and control groups between prior
orthopedic studies. Since no orthopedic study has com-
p a r e dT X Aa n dE A C At o g e t h e r ,c o n d u c t i n gap o w e r
analysis required pooling of data from two or three stu-
dies. This proved difficult, as control groups were dis-
similar between the studies (Table 2).
Power analysis was performed multiple times using
data from several studies. When estimating the sample
size required comparing TXA and EACA, attempts were
made to choose two studies with similar intra-operative
blood losses within the control groups. A cardiac study,
albeit with dissimilar sample variance, was also used to
estimate the sample size needed for this study. Finally,
determining the sample size for outcomes of total blood
loss and transfusion requirements proved difficult as
even fewer studies reported these outcomes. Blood loss
will be estimated in the operation room, but will also be
calculated taking into account patient body mass, pre/
postoperative hematocrit, and relative fluid balance
[21-23]. This will minimize the variance in reported
blood loss. A power analysis will be performed again
once 60 patients with AIS, NMS, or AD have been
enrolled into the study.
With a single institution of surgeons and anesthesiolo-
gists participating in the study, we expect a smaller var-
iation in operative blood loss than reported in prior
studies. Data will not only be analyzed for all patients
collectively, but will also be stratified by diagnosis (AIS,
NMS, and AD). The purpose of stratifying into these
groups is threefold. First, separation by diagnosis allows
for more diligent control of patient-related factors that
may affect blood loss and transfusion rate. Secondarily,
stratification by diagnosis allows for a better under-
standing of which patients benefit most from one treat-
ment option over another. Lastly, it allows for a broader
application of the results from this study not only to
patients with AIS, but to all spinal deformity patients.
An analysis of variance, univariate, and multivariate
logistic regression analysis will be used to analyze the
difference in outcomes. Odds ratios will be calculated
regarding the risk for autologous or allogenic trans-
fusion both intra and postoperatively. P-values will be
calculated regarding the relative blood loss in the intra
and postoperative periods as well. The groups will
be analyzed to characterize the homogeneity of their
Table 3 Power study to determine number of patients needed for NMS group
TXA Amicar Control
Blood
loss
Standard
Deviation
Blood
Loss
Standard
Deviation
Blood
Loss
Standard
Deviation
Sample Size
Needed
Intra-op blood loss 1408 mL +/- 605 mL - - 2690 mL +/- 1266 mL 14
Intra-op blood loss 1976 mL +/- 860 mL 1117 mL +/- 718 mL - - 30
Total blood
transfused
808 mL +/- 531 mL - - 1391 mL +/- 723 mL 34
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loss. Patients with AIS, NMS or AD will be stratified by
primary diagnosis and analyzed separately but also col-
lectively accounting for patient and surgery-related con-
founders. Non-continuous data will be analyzed with a
non-parametric test. Pre-operative curve characteristics
including Cobb angle and number of vertebrae fused
will be categorized to ensure similar groups for
comparison.
Discussion
Overall, orthopedic studies have demonstrated the effi-
cacy of TXA and EACA over placebo in relation to
blood loss [8-16]. However, the specifics of this demon-
strated benefit are lacking. In particular, a reduction in
intra-operative blood loss has been inconsistently
reported. In two recent Cochrane reviews, TXA was
noted to be more efficacious than EACA at reducing
total blood loss, but neither drug significantly reduced
intra-operative bleeding [7,8]. The most recent review
demonstrated a reduction in transfusion volume with
antifibrinolytic medications in scoliosis surgery, but
could not comment on the benefit of one medication
over another [7,8]. In addition, studies solely reporting
intra-operative blood losses may have overlooked post-
operative benefits. The authors concluded that antifibri-
nolytic treatments have greatest efficacy in controlling
postoperative bleeding, but also that more investigation
was needed. Comparing trials in all surgical fields
including cardiac surgery, TXA - but not EACA - was
found to reduce the transfusion rate over placebo.
The cardiac literature has produced seven prospective
studies comparing TXA and EACA head-to-head, but no
trial was assessed as having proper patient randomization
and physician blinding [7,18-20]. Moreover, for five of
the seven trials the method of randomization raised
uncertainty for the reviewers [7]. In addition, the trials
were inappropriately powered to detect differences
between TXA and EACA and excluded high-risk patients
to accentuate differences between the two drugs.
The role of anti-fibrinolytics to manage blood loss,
therefore, remains largely surgeon dependent and is not
the standard of care in spinal deformity surgery. Of the
scoliosis studies examined in the Cochrane review, only
two studies adequately randomized patients and blinded
both the surgeon and anesthesiologist to the patient’s
treatment [8]. Since operative blood loss is partly depen-
dent upon surgical and anesthetic conditions, proper
physician blinding is imperative. As stated, no single
orthopedic study has prospectively compared the relative
efficacy of TXA and EACA head-to-head.
The goal of this proposal is to perform a randomized,
prospective, double blind study comparing the relative
efficacy of TXA, EACA, and controls in AIS, NMS, and
AD patients. AIS patients are particularly well suited to
investigate because these patients are generally healthy,
and free from use of anticoagulant medications. These
factors all help to minimize the effect of known con-
founders effecting blood loss. Patients with NMS, how-
ever, have a heterogonous profile and often have
multiple confounding medical problems that may affect
blood loss. Typically these patients have significant lar-
ger blood loss and transfusion needs as compared to
AIS patients. However, this difference may accentuate
differences in blood loss for TXA versus EACA. Finally,
AD patients represent the largest subgroup of spinal
deformity patients. Their inclusion into this study allows
for the results to have a broader application across
spinal deformity patients.
We hope that this study will determine if a difference
in efficacy exists between TXA, EACA and placebo and
begin to establish a new standard of care in corrective
spinal surgery. The use of patient populations beyond
those of AIS may have meaningful results that can be
applied to a wider range of patients undergoing correc-
tive spinal procedures by reducing morbidities asso-
ciated with blood loss.
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